ProKidney Corp. - Class A Ordinary Shares — Liquidità (NASDAQ:PROK) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative —-77.09 M-90.07 M-126.35 M-120.12 M -132.21 M Flussi di cassa derivanti dalle attività di investimento —-1.74 M-329.98 M20.41 M103.97 M 110.5 M Liquidità derivante dalle attività di finanziamento —548.52 M-9.55 M144.41 M25.57 M 25.8 M Liquidità libera —-77.09 M-90.07 M-126.35 M-135.31 M -150.06 M

Notizie

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

ProKidney nomina Greg Madison come chief commercial officer

BofA conferma rating Underperform su ProKidney con target a $1

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright avvia copertura su ProKidney con rating Buy e target di $12

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target